In a randomised controlled trial of 51 adolescents with major depressive disorder and suicidal ideation, three subanaesthetic esketamine infusions (0.25 mg/kg) did not impair cognition and were associated with improved processing speed and some improvement in working memory by Day 12. Baseline cognitive performance did not predict antidepressant or antisuicidal response.
- Published
- Journal
- Child and Adolescent Psychiatry
- Authors
- Lan, X-F., Wang, C-Y., Zhang, F., Liu, H., Mai, S., Ning, Y-P., Zhou, Y-L., Hu, Z., Li, W., Ye, Y.